San Raffaele Registry on Liver Cancer
This is a Retrospective and Prospective Observational Single-Center Study. The purpose is to collect all data to generate a registry of primary liver cancer (hepatocellular carcinoma and biliary tract carcinoma) of patients accessing to San Raffaele Hospital. An additional purpose is to identify novel biomarkers to better manage primary liver cancer patients, for whom additional biological samples will be collected.
A total of 4000 patients will be enrolled; for the prospective cohort: from protocol approval to the achievement of the last planned patients in the prospective cohort (2000 patients). The retrospective cohort will start from the year 2000.
Patients will be followed for 5 years of follow-up.
Przegląd badań
Status
Szczegółowy opis
The object of the study is to collect all data from patients with primary liver diseases (hepatocellular carcinoma or BTC), investigating any correlation with clinical and/or molecular characteristics. As exploratory analysis, the project will explore the possible identification of any immunological, genetic, histological, cellular, molecular, and/or microbiological biomarker that could support patients' management.
Data collection of enrolled patients will cover all initial information regarding patient disease characteristics and profiling and all follow-up data available, included any data generated by other hospitals but referring to the disease studied. As this is an observational study, there will be no modification to any existing treatment pathways for patients. The only additional procedures are the collection of some biological samples at different timepoints (baseline, 3, 6, 9, 12 months and at disease progression):
- Additional blood volumes (approximately 30 mL) to collect during routinary blood exams
- Saliva
- Stool
Moreover, also tumor tissue will be investigated for exploratory analysis. In particular, tumor tissue collected according to normal clinical practice (baseline, eventually surgery, and/or re-biopsy), if still available after diagnostic purpose, will be analyzed to seek novel biomarkers. Additionally to FFPE archivial tumor tissue, exceeding fresh tumor tissue from diagnostic purpose, may be stored in other media other than paraffin (for example OTC).
A total of 4000 patients will be enrolled; for the prospective cohort: from protocol approval to the achievement of the last planned patients in the prospective cohort (2000 patients). The retrospective cohort will start from the year 2000.
Patients will be followed for 5 years of follow-up.
Typ studiów
Zapisy (Szacowany)
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Andrea Casadei Gardini, Medical Oncologist
- Numer telefonu: +390226437627
- E-mail: CasadeiGardini.Andrea@hsr.it
Lokalizacje studiów
-
-
-
Milan, Włochy
- Rekrutacyjny
- IRCCS Ospedale San Raffaele
-
Kontakt:
- Andrea Casadei Gardini, Medical Oncologist
- Numer telefonu: +390226437627
- E-mail: CasadeiGardini.Andrea@hsr.it
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
- Dorosły
- Starszy dorosły
Akceptuje zdrowych ochotników
Metoda próbkowania
Badana populacja
Opis
Inclusion Criteria:
- Participant is willing and able to give informed consent for participation in the study. However, concerning the retrospective cohort, the large sample sizes needed and considering that the disease involved in this study affects elderly subjects with co-morbidities and presents a significant mortality rate based on the stage of the disease, deceased and untraceable patients will also be included.
- ≥18 years of age.
- Patients diagnosed with any subtype of biliary tract cancer (i.e. iCCA, pCCA, dCCA or GBC) at every stage and with all therapeutic indications.
- Patients diagnosed with hepatocellular carcinoma at every stage and treated with all therapeutic options.
Exclusion Criteria:
1. Patients without diagnosis of hepatocellular carcinoma or biliary tract cancer (BTC).
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
Kohorty i interwencje
Grupa / Kohorta |
|---|
|
Patients with diagnosis of primary liver cancer
Patients with diagnosis of hepatocellular carcinoma or biliary tract cancer presenting to IRCCS Ospedale San Raffaele will be included
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
To collect clinical data from patients with primary liver disease
Ramy czasowe: From date of diagnosis until the date of death from any cause or last follow up, assessed up to 5 years
|
Collection of all clinical data from patients with primary liver disease
|
From date of diagnosis until the date of death from any cause or last follow up, assessed up to 5 years
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
To seek correlation between clinical and molecular data with PFS outcome
Ramy czasowe: From date of start of each treatment line until the date of first documented progression or date of death from any cause, assessed up to 12 months. Tumor assessments will be performed in accordance with clinical practice
|
-Progression-free survival (PFS), defined as the time from the start of each treatment line to the first documented disease progression or death from any cause, whichever occurs first, according to RECIST version 1.1.
PFS will be assessed separately for each treatment line received by the patien
|
From date of start of each treatment line until the date of first documented progression or date of death from any cause, assessed up to 12 months. Tumor assessments will be performed in accordance with clinical practice
|
|
To seek correlation between clinical and molecular data with OS outcome
Ramy czasowe: From date of diagnosis until the date of death from any cause or last follow up, assessed up to 5 years
|
Overall survival, defined as the time from diagnosis to death from any cause.
|
From date of diagnosis until the date of death from any cause or last follow up, assessed up to 5 years
|
|
To seek correlation between clinical and molecular data with Toxicity outcome
Ramy czasowe: From treatment initiation until the date of death from any cause or last follow up, assessed up to 5 years
|
Frequency and severity of adverse events related to treatment, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v.6.
|
From treatment initiation until the date of death from any cause or last follow up, assessed up to 5 years
|
|
To seek correlation between clinical and molecular data with DFS outcome
Ramy czasowe: From date of surgery or complete response until the date of first documented recurrence or date of death from any cause, whichever came first, assessed up to 5 years. Tumor assessments will be performed in accordance with clinical practice
|
DFS: Time from complete response or radical surgery to disease recurrence or death from any cause
|
From date of surgery or complete response until the date of first documented recurrence or date of death from any cause, whichever came first, assessed up to 5 years. Tumor assessments will be performed in accordance with clinical practice
|
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
To seek potential immunological biomarker
Ramy czasowe: Baseline, 3, 6, 9, 12 months, and at disease progression (PD)
|
Changes in immunological biomarkers will be assessed through the evaluation of soluble factors (such as cytokines) and immunophenotype of circulating and tumor-resident immune cells.
|
Baseline, 3, 6, 9, 12 months, and at disease progression (PD)
|
|
To seek potential genetic biomarker
Ramy czasowe: Baseline, 3, 6, 9, 12 months, and at disease progression (PD)
|
Prevalence and type of somatic genetic alterations in tumor tissue assessed with Next-Generation Sequencing (NGS).
|
Baseline, 3, 6, 9, 12 months, and at disease progression (PD)
|
|
To seek potential histological biomarker
Ramy czasowe: Baseline, 3, 6, 9, 12 months, and at disease progression (PD)
|
Histological tumor features will be assessed using high-throughput approaches, including multiplexed immunohistochemistry (IHC), to explore novel prognostic and/or predictive biomarkers.
|
Baseline, 3, 6, 9, 12 months, and at disease progression (PD)
|
Współpracownicy i badacze
Sponsor
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- SR Liver Cancer Registry
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .